Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apalutamide with Intermittent Hormone Therapy in Prostate Cancer
NCT02811809Phase 2Withdrawn
- Sponsor
- UTHealth Houston
- Start
- Dec 2020
- Primary completion
- Dec 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of apalutamide in prostate cancer (PCa), sponsored by UTHealth Houston. Planned start Dec 2020; status: withdrawn.
02
Drugs
apalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02811809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02811809.